Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maxim Pharmaceuticals has achieved a $1 million development milestone under an agreement with Myriad Genetics. The milestone is based on the dosing of the first patient in a phase I clinical program evaluating MPC-6827 in patients with advanced solid tumors.
Subscribe to our email newsletter
MPC-6827 is being developed by Myriad from a family of anticancer analogs discovered by Maxim through its proprietary high-throughput screening system, which identifies compounds and molecular targets that induce programmed cell death, or apoptosis.
In preclinical studies, MPC-6827 was notable in its breadth of activity, demonstrating activity that was better than control using current standard-of-care chemotherapy in xenograft models of breast, pancreas, colon, ovary and prostate cancers. The compound targets a novel intracellular target and shows selectivity for breast and colorectal cancer.
“We are very pleased with Myriad’s progress in the MPC-6827 program and look forward to the phase I study results,” stated Larry Stambaugh, Maxim’s chairman and CEO. “In the meantime we are continuing our efforts to advance other anticancer compounds into the clinic.”